Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus MYCITRACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus MYCITRACIN.
KERLEDEX vs MYCITRACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
500 mg orally every 6 hours
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Corticosteroid/Antibiotic Combination
Antibiotic Combination